Clinical and angiographic outcome after interventional treatment of the iliac arteries with a new carbofilm coated stent: preliminary results.
OBJECTIVE
To evaluate the handling, the procedural success rate and the six-month outcome of a new Carbofilm coated balloon-expandable stent in iliac artery lesions.


METHODS
In a prospective study, 46 stenoses and 2 occlusions of the iliac arteries were primarily stented in 30 patients with the Isthmus CarboStent (Sorin Biomedica Cardio S.p. A., Saluggia, Italy). The ankle-brachial index (ABI) at rest was determined before intervention and at the six-month follow-up visit. Iliac angiography, including intraarterial pressure measurement, was performed before intervention, post-procedurally and at the follow-up visit.


RESULTS
All lesions were treated with procedural success. The mean degree of all stenoses was 73.9 % +/- 14.6 before and 2.4 % +/- 8.2 after intervention. The mean pressure gradient was 15.6 mm Hg +/- 10.1 before and 2.5 mm Hg +/- 2.7 after treatment. No or only a mild restenosis developed in 27 patients. The mean ABI increased from 0.64 +/- 0.21 to 0.86 +/- 0.33 and the mean pressure gradient was 2.7 mm Hg +/- 5.4 at the six-month visit. The six-month patency rate was 97.9 %. Three patients showed acute stent thrombosis due to an insufficient postprocedural antiplatelet regimen.


CONCLUSIONS
The Isthmus CarboStent is a safe and easy to handle balloon-expandable stent for interventional therapy of iliac artery lesions. The six-month patency rate is good. Despite its Carbofilm coating, postprocedural antiplatelet therapy is necessary.
Butz
B
B
Department of Radiology, University of Regensburg Hospital, Regensburg, Germany. bernhard.butz@klinik.uni-regensburg.de
Paetzel
C
C
Stern
U
U
Schleicher
T
T
Pfister
K
K
Link
J
J
Feuerbach
S
S
Lenhart
M
M
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000792:Angiography; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000601:surgery*; D001161:Arteriosclerosis / Q000000981:diagnostic imaging / Q000601:surgery; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D002244:Carbon; D000077144:Clopidogrel; D003251:Constriction, Pathologic / Q000000981:diagnostic imaging / Q000601:surgery; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007083:Iliac Artery / Q000000981:diagnostic imaging; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000000981:diagnostic imaging / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014654:Vascular Patency
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D002244:Carbon; D006493:Heparin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin